Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2017 Jan 29

PMID 28130788

Citations 676

Authors

Parambir S Dulai

Siddharth Singh

Janki Patel

Meera Soni

Larry J Prokop

Zobair Younossi

Giada Sebastiani

Mattias Ekstedt

Hannes Hagstrom

Patrik Nasr

Per Stal

Vincent Wai-Sun Wong

Stergios Kechagias

Rolf Hultcrantz

Rohit Loomba

Affiliations

Soon will be listed here.

Abstract

Conclusion: The risk of liver-related mortality increases exponentially with increase in fibrosis stage; these data have important implications in assessing the utility of each stage and benefits of regression of fibrosis from one stage to another. (Hepatology 2017;65:1557-1565).

Citing Articles

The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease.

Amin M, Sadik N, Saad H, Fawzy M, Elsheimy H Intern Emerg Med. 2025; .

PMID: 40085410 DOI: 10.1007/s11739-025-03902-w.

The association between estimated glucose disposal rate and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in US adults.

Liu W, Li X, Chen L, Luo X BMC Endocr Disord. 2025; 25(1):67.

PMID: 40065306 PMC: 11895387. DOI: 10.1186/s12902-025-01891-7.

Advanced Liver Fibrosis Impairs Cardiorespiratory Fitness in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.

Sogbe M, Hummer B, Stine J, Lizaola-Mayo B, Forman D, Vargas H Dig Dis Sci. 2025; .

PMID: 39966289 DOI: 10.1007/s10620-025-08893-4.

Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis.

Saeed A, Rai K, Saeed M Liver Res. 2025; 8(3):193-194.

PMID: 39957747 PMC: 11771249. DOI: 10.1016/j.livres.2024.07.002.

Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study.

Liang Y, Ye X, Pan M, Chen Y, Yuan Y, Luo L BMC Gastroenterol. 2025; 25(1):75.

PMID: 39934679 PMC: 11818238. DOI: 10.1186/s12876-025-03661-0.

References

Leung J, Loong T, Wei J, Wong G, Chan A, Choi P . Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2016; 65(1):54-64. DOI: 10.1002/hep.28697. View

Stepanova M, de Avila L, Afendy M, Younossi I, Pham H, Cable R . Direct and Indirect Economic Burden of Chronic Liver Disease in the United States. Clin Gastroenterol Hepatol. 2016; 15(5):759-766.e5. DOI: 10.1016/j.cgh.2016.07.020. View

Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S . Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol. 2014; 20(39):14185-204. PMC: 4202348. DOI: 10.3748/wjg.v20.i39.14185. View

Goossens N, Hoshida Y, Song W, Jung M, Morel P, Nakagawa S . Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. Clin Gastroenterol Hepatol. 2015; 14(11):1619-1628. PMC: 4838546. DOI: 10.1016/j.cgh.2015.10.010. View

Targher G, Byrne C, Lonardo A, Zoppini G, Barbui C . Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65(3):589-600. DOI: 10.1016/j.jhep.2016.05.013. View

Dulai P, Sirlin C, Loomba R . MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016; 65(5):1006-1016. PMC: 5124376. DOI: 10.1016/j.jhep.2016.06.005. View

Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View

Noureddin M, Anstee Q, Loomba R . Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2016; 43(11):1109-23. PMC: 5906100. DOI: 10.1111/apt.13620. View

Doycheva I, Cui J, Nguyen P, Costa E, Hooker J, Hofflich H . Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2015; 43(1):83-95. PMC: 4673036. DOI: 10.1111/apt.13405. View

10.

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

11.

Tapper E, Hunink M, Afdhal N, Lai M, Sengupta N . Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. PLoS One. 2016; 11(2):e0147237. PMC: 4764354. DOI: 10.1371/journal.pone.0147237. View

12.

Rinella M . Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015; 313(22):2263-73. DOI: 10.1001/jama.2015.5370. View

13.

Matteoni C, Younossi Z, Gramlich T, Boparai N, Liu Y, McCullough A . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6):1413-9. DOI: 10.1016/s0016-5085(99)70506-8. View

14.

Younossi Z, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R . Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011; 53(6):1874-82. DOI: 10.1002/hep.24268. View

15.

Adams L, Lymp J, Sauver J, Sanderson S, Lindor K, Feldstein A . The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129(1):113-21. DOI: 10.1053/j.gastro.2005.04.014. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

17.

Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C . Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology. 2015; 63(3):827-38. DOI: 10.1002/hep.28368. View

18.

Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P . Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One. 2015; 10(6):e0128774. PMC: 4471234. DOI: 10.1371/journal.pone.0128774. View

19.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

20.

Angulo P, Kleiner D, Dam-Larsen S, Adams L, Bjornsson E, Charatcharoenwitthaya P . Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015; 149(2):389-97.e10. PMC: 4516664. DOI: 10.1053/j.gastro.2015.04.043. View